CAI vs NDAQ · rev $812.0M vs P/E 41, rev $2.53B
Caris Life Sciences, Inc. Common Stock (CAI) versus Nasdaq Inc (NDAQ) — a side-by-side from cached financials, not a winner call.
Caris Life Sciences, Inc. Common Stock (CAI) is a biotechnology company listed on NASDAQ.
Nasdaq Inc (NDAQ) is a financial data & stock exchanges company listed on US.
Latest reported CAI revenue for 2025-12-31 was $812.0M. Net income was -$68.1M. Revenue was up 97.0% from 2024-12-31 to 2025-12-31. CAI currently screens at market cap $5.22B.
Latest reported NDAQ revenue for 2026-06-30 was $2.53B. Net income was $507.0M. Revenue was up 18.5% from 2026-03-31 to 2026-06-30. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
CAI currently screens at market cap $5.22B. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
Not investment advice. Open the CAI and NDAQ stock pages for the full models.
Not investment advice.